<DOC>
	<DOCNO>NCT00470548</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop dividing . Pemetrexed may stop growth tumor cell block enzymes need cell growth . Giving paclitaxel albumin-stabilized nanoparticle formulation together pemetrexed may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose paclitaxel albumin-stabilized nanoparticle formulation give together pemetrexed see well work treat patient advance non-small cell lung cancer , breast cancer , solid tumor .</brief_summary>
	<brief_title>Abraxane Alimta Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility paclitaxel albumin-stabilized nanoparticle formulation administer pemetrexed disodium patient advance non-small cell lung cancer , breast cancer , solid tumor . ( Phase I ) - Determine efficacy regimen , measure objective tumor response rate ( RECIST criterion ) , patient . ( Phase II ) Secondary - Determine maximum tolerate dose regimen patient . ( Phase I ) - Determine preliminary efficacy paclitaxel albumin-stabilized nanoparticle formulation pemetrexed disodium patient . ( Phase I ) - Determine progression-free survival overall survival patient treat regimen . ( Phase II ) - Evaluate frequency severity toxicity associate regimen . ( Phase II ) OUTLINE : This phase I , dose-escalation study paclitaxel albumin-stabilized nanoparticle formulation follow open-label , phase II study . - Phase I : Patients receive pemetrexed disodium IV 10 minute paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos paclitaxel albumin-stabilized nanoparticle formulation maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive pemetrexed disodium paclitaxel albumin-stabilized nanoparticle formulation MTD phase I . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion Criteria 1 . For phase II portion patient must cytologically histologically proven select stage IIIB ( pleural effusion ) IV NSCLC . 2 . For phase II portion patient must NSCLC progressed recur treatment platinumbased therapy . 3 . No prior pemetrexed . Prior Taxol allow . Prior ABI 007 allow . 4 . Patients must measurable disease RECIST criterion phase II portion . 5 . Patients must 18 year age old . 6 . Patients must performance status 0 2 7 . Patients must estimate survival least 3 month . 8 . Any prior chemotherapy must complete least 4 week prior start treatment . 9 . Patients must adequate renal function document calculated creatinine clearance &gt; 45 ml/min 10 . Patients must adequate liver function : AST ALT &lt; 2.5 X upper limit normal , bilirubin &lt; upper limit normal . 11 . Patients must adequate bone marrow function : Platelets &gt; 100,000 cells/mm3 ANC &gt; 1,500 cells/mm3 . 12 . For patient baseline clinically significant pleural peritoneal effusion ( basis symptom clinical examination ) initiation pemetrexed therapy , consideration give drain effusion prior dose . 13 . Patients asymptomatic treat brain metastasis ( surgical resection radiotherapy ) may include neurologically stable steroid anticonvulsant least 4 week . 14 . Patients must able take retain oral medication . 15 . Ability take folic acid , vitamin B12 dexamethasone accord protocol . 16 . Ability interrupt NSAIDS 2 day , day , 2 day follow administration pemetrexed . 17 . Patients reproductive potential must agree use effective contraceptive method treatment 3 month afterwards effect drug unborn fetus unknown . 18 . No current active malignancy . 19 . Patient his/her legally authorize representative guardian sign Informed Consent form prior participation studyrelated activity . Exclusion Criteria 1 . Pregnant breastfeed woman . 2 . Patient preexist peripheral neuropathy NCI CTCAE Version 3.0 grade 2 . 3 . Patient clinically significant concurrent illness . 4 . Patient currently enrol different clinical study investigational procedure perform investigational therapy administer . 5 . Patient history allergy hypersensitivity study drug taxane . 6 . Patient serious medical risk factor involve major organ system investigator considers unsafe patient receive experimental research drug . 7 . Prior therapy pemetrexed , ABI007 . 8 . Patient receive treatment exclude concomitant medication . 9 . Presence third space fluid control drainage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>